gti8k81210.htm
 
 
SECURITIES AND EXCHANGE COMMISSION
 
 
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (August 12, 2010):  August 12, 2010
 
GUIDED THERAPEUTICS, INC.
 (Exact Name of Registrant as Specified in Its Charter)
 
         
Delaware
(State or Other Jurisdiction of Incorporation)
  
0-22179
(Commission File Number)
  
58-2029543
(IRS Employer Identification No.)

   
5835 Peachtree Corners East, Suite D
Norcross, Georgia
(Address of Principal Executive Offices)
30092
(Zip Code)
 
Registrant's Telephone Number, Including Area Code:     (770) 242-8723
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions :
 
 
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
 
 
 
 
 
 
 
 
 

 
Section 8.01  Other Events
 
On August 12, 2010, Guided Therapeutics, Inc. (OTCBB: GTHP) announced its operating results for the second quarter and first six months of 2010 as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.
 
Item 9.01  Financial Statements and Exhibits

The following exhibits are filed with this report:
 
 Exhibit No.     Description
 99.1  Press Release dated August 12, 2010
 
 
 
 
 
 
 
 
 
 
 
 
2
 

 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
     GUIDED THERAPEUTICS, INC  
       
   By:  /s/ MARK L. FAUPEL  
                                                                                                                                                                                                                  Mark L. Faupel, Ph.D.  
     CEO & President  
 Date:  August 12, 2010      
 
 
 
 
 
 
 
 
 
3